证券之星消息，截至2025年11月25日收盘，天臣医疗(688013)报收于49.66元，下跌1.27%，换手率 1.51%，成交量1.22万手，成交额6128.31万元。 11月25日的资金流向数据方面，主力资金净流出236.22万元，占总成交额3.85%，游资资金净流出 251.76万元，占总成交额4.11%，散户资金净流入487.99万元，占总成交额7.96%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-25 | 49.66 -1.27% | -236.22万 | -3.85% | -251.76万 | -4.11% | 487.99万 | 7.96% | | 2025-11-24 | 50.30 0.40% | -1054.22万 | -9.87% | -422.32万 | -3.95% | 1476.53万 | 13.83% | | 2025-11-21 | 50.10 -5.1 ...

截至2025年11月21日收盘，天臣医疗（688013）报收于50.1元，较上周的56.0元下跌10.54%。本周，天 臣医疗11月17日盘中最高价报56.7元。11月21日盘中最低价报49.32元。天臣医疗当前最新总市值40.66 亿元，在医疗器械板块市值排名84/126，在两市A股市值排名3761/5167。 天臣医疗关于召开2025年第三季度业绩说明会的公告 天臣医疗将于2025年12月3日16:00-17:00通过上证路演中心网络文字互动方式召开2025年第三季度业绩 说明会，介绍公司经营成果、财务状况等情况。参会人员包括董事长陈望宇、总经理陈望东、财务总监 田国玉等。投资者可于11月26日至12月2日16:00前通过上证路演中心或公司邮箱提交问题。说明会结束 后可通过该平台查看会议内容。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 公司公告汇总：天臣医疗将于2025年12月3日召开第三季度业绩说明会，投资者可提前提交问题。 公司公告汇总 ...

截至2025年11月21日收盘，天臣医疗（688013）报收于50.1元，较前一交易日下跌5.11%，最新总市值 为40.66亿元。该股当日开盘52.1元，最高52.3元，最低49.32元，成交额达5763.26万元，换手率为 1.4%。 最新公告列表 《天臣医疗关于召开2025年第三季度业绩说明会的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，天臣医疗发布关于召开2025年第三季度业绩说明会的公告。公司将于2025年12月3日16:00-17:00 通过上证路演中心网络文字互动方式召开2025年第三季度业绩说明会，介绍公司经营成果、财务状况等 情况。参会人员包括董事长陈望宇、总经理陈望东、财务总监田国玉等。投资者可于11月26日至12月2 日16:00前通过上证路演中心或公司邮箱提交问题。说明会结束后可通过该平台查看会议内容。 ...

Core Viewpoint - Tianchen Medical (688013) experienced a decline in stock price, closing at 50.1 yuan on November 21, 2025, down 5.11% from the previous day [1] Group 1: Stock Performance - On November 21, 2025, the stock had a turnover rate of 1.4%, with a trading volume of 11,400 hands and a transaction amount of 57.63 million yuan [1] - The net outflow of main funds was 790.2 thousand yuan, accounting for 13.71% of the total transaction amount, while retail investors saw a net inflow of 249.53 thousand yuan, representing 4.33% of the total [1] Group 2: Recent Fund Flow - Over the past five days, the stock's closing prices and changes were as follows: - November 21: 50.10 yuan, -5.11% - November 20: 52.80 yuan, -1.35% - November 19: 53.52 yuan, -3.22% - November 18: 55.30 yuan, +1.19% - November 17: 54.65 yuan, -2.41% [2] Group 3: Company Financials and Industry Comparison - Tianchen Medical's total market value is 4.066 billion yuan, with a net asset of 600 million yuan and a net profit of 71.95 million yuan [3] - The company reported a year-on-year revenue increase of 20.66% for the first three quarters of 2025, with a net profit growth of 68.29% [3] - The gross profit margin stands at 63.22%, significantly higher than the industry average of 51.22% [3] - The company ranks 9th in return on equity (ROE) within the industry at 12.52% [3]

证券代码：688013 证券简称：天臣医疗 公告编号：2025-063 天臣国际医疗科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开时间：2025 年 12 月 3 日（星期三）16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 11 月 26 日（星期三）至 12 月 2 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 tsbs@touchstone.hk）将需要了解和关注的问题提前提供给公司。公司将在说明 会上对投资者普遍关注的问题 ...

Financial Performance - The company reported a revenue of 244 million yuan for the first three quarters, representing a year-on-year increase of 20.66% [1] - The net profit attributable to shareholders was 71.95 million yuan, up 68.29% year-on-year [1] - The net profit excluding non-recurring items was 66.20 million yuan, reflecting a 71.85% increase compared to the previous year [1] - Basic earnings per share were 0.90 yuan [1] Profitability Metrics - The gross margin for the first three quarters was 63.22%, an increase of 5.02 percentage points year-on-year [1] - The net profit margin was 29.51%, which is an increase of 8.35 percentage points compared to the same period last year [1] Operating Expenses - Operating expenses for the first three quarters amounted to 78.22 million yuan, an increase of 3.96 million yuan year-on-year [1] - The operating expense ratio was 32.08%, a decrease of 4.67 percentage points from the previous year [1] - Sales expenses increased by 20.04%, management expenses rose by 8.16%, and R&D expenses grew by 16.47%, while financial expenses decreased by 251.22 thousand yuan [1] Leadership Compensation - The chairman and the general manager of the company, Chen Wangyu and Chen Wangdong, received a salary of 1.104 million yuan each in 2024 [3] Shareholding Structure - The controlling shareholders, Chen Wangyu and Chen Wangdong, are brothers, holding 25.85% and 25.79% of the shares respectively [4] Company Background - The company, Tianchen Medical, is located in Suzhou Industrial Park, Jiangsu Province, and was established on August 18, 2003 [7] - It specializes in the research, innovation, production, and sales of high-end surgical staplers [7]

Core Viewpoint - The company is making steady progress on its MA project, which involves the development of an integrated intelligent surgical platform and execution terminal, and is currently in the process of technical performance validation [1] Group 1 - The MA project is advancing as planned, with the production line's process validation completed [1] - The company is conducting rigorous technical performance validation for the product [1] - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations regarding future project updates [1]

Core Viewpoint - Tianchen Medical (688013) experienced a decline in stock price, closing at 56.0 yuan on November 14, 2025, with a drop of 2.12% [1] Group 1: Stock Performance and Trading Data - On November 14, 2025, the trading volume was 14,400 hands, with a total transaction amount of 81.39 million yuan [1] - The net inflow of main funds was 4.10 million yuan, accounting for 5.04% of the total transaction amount, while retail investors had a net outflow of 6.95 million yuan, representing 8.54% of the total [1] - Over the past five days, the stock price fluctuated, with a peak closing price of 57.21 yuan on November 13, 2025, and a low of 52.68 yuan on November 11, 2025 [2] Group 2: Financial Performance and Industry Comparison - For the first three quarters of 2025, Tianchen Medical reported a main revenue of 244 million yuan, a year-on-year increase of 20.66%, and a net profit of 71.95 million yuan, up 68.29% year-on-year [3] - The company's gross profit margin stands at 63.22%, significantly higher than the industry average of 51.22%, and its net profit margin is 29.51%, compared to the industry average of 9.57% [3] - Tianchen Medical's total market value is 4.545 billion yuan, with a net asset of 600 million yuan, and it ranks 78th in the industry for market value and 115th for net assets [3]

Group 1 - The company is progressing as planned with its MA project, which involves the development of an integrated intelligent surgical platform [2] - The production line's process validation has been completed, and the company is currently conducting rigorous technical performance validation of the product [2] - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations regarding the project's subsequent progress [2]

Core Viewpoint - The company is making progress on its intensive smart surgical platform and execution terminal (MA) project, with production line process validation completed and ongoing rigorous technical performance validation [1] Group 1 - The company is currently developing an intensive smart surgical platform [1] - The execution terminal (MA) project is advancing as planned [1] - Production line process validation has been completed [1] - The company is conducting strict technical performance validation for its products [1]